Tuesday, November 18, 2014

Web Seminar: Global Rise of Chronic and Age related Diseases: Trends in Clinical Development Globally

Global Rise of Chronic and Age related Diseases: Trends in Clinical Development Globally
Presenter: Laura Runkel, Associate Director of CNS, 
Autoimmune/Inflammation & Ophthalmology, Citeline
Join us for a webinar on Dec 17, 2014 at 2:00 PM EST.
Register now!
Mention priority code XP2000W3BLOG

About the web seminar:
Chronic and age related diseases are on the rise globally. Given the demographics of an aging population and life style changes in the high income countries, this marked rise in chronic diseases is projected to continue into the future. Clinical trial activity in these diseases has increased globally as treatments are sought to address the substantial unmet need. Case studies for drug and clinical trial activity in two serious diseases, chronic obstructive pulmonary disease (COPD) and Alzheimer’s disease, will profile the current therapeutic landscape to gain key insights into successful programs and to gauge future prospects.

Several novel fixed-dose combination (FDC) therapies were approved in 2013 for COPD maintenance therapy. The analysis of study design and timelines provides a current snapshot of the COPD landscape and a look at the future for pipeline FDC competitors still in development. Standard of care for Alzheimer’s disease includes cognition enhancing drugs that provide limited symptom relief and have no impact on disease progression. Hope for a treatment that halts or slows the progression of Alzheimer’s disease lies with the development of disease modifying therapeutics. The early clinical disappointments for beta amyloid antagonists have created an opportunity to improve clinical trial design and AD diagnosis. A paradigm shift is reflected in current AD clinical trial design by top industry sponsors.

What you will learn:
  • • The utility of Citeline’s integrated drugs, trials and timelines solutions for analysis of clinical development status/trends
  • • Key insights into the success of COPD FDC clinical programs
  • • The current competitive landscape for pipeline FDCs in COPD
  • • How treatment of earlier stage Alzheimer’s disease is occurring for disease modifying drugs
  • • What are the top industry sponsors, drugs, and clinical timelines for pipeline Alzheimer’s disease therapies

This web seminar is produced in coordination with Partnerships in Clinical Trials. 

No comments: